Portal de Periódicos da CAPES

The role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trial

2022; Future Medicine; Volume: 18; Issue: 36 Linguagem: Inglês

10.2217/fon-2022-0840

1744-8301

Kerrington Powell, John Marquart, Timothée Olivier, Vinay Prasad,

CAR-T cell therapy research

Future OncologyVol. 18, No. 36 CommentaryThe role of surgery in metastatic cancer: the case for a pragmatic tumor-agnostic randomized trialKerrington Powell, John Marquart, Timothée Olivier & Vinay PrasadKerrington Powell https://orcid.org/0000-0001-7067-3559School of Medicine, Texas A&M Health Science Center, Bryan, TX 77807, USA, John MarquartDepartment of Surgery, Medical College of Wisconsin, 999 North 92nd Street, Suite CCC 320, Milwaukee, WI 53226, USA, Timothée Olivier https://orcid.org/0000-0002-6936-5783Department of Oncology, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205, Geneva, SwitzerlandDepartment of Epidemiology & Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA & Vinay Prasad *Author for correspondence: E-mail Address: vinayak.prasad@ucsf.eduhttps://orcid.org/0000-0002-6110-8221Department of Epidemiology & Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USAPublished Online:9 Jan 2023https://doi.org/10.2217/fon-2022-0840AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: biomarkersclinical trialsmetastasismolecular oncologyoncogenessurgeryReferences1. Bartlett EK, Simmons KD, Wachtel H et al. The rise in metastasectomy across cancer types over the past decade. Cancer 121(5), 747–757 (2015).Crossref, Medline, Google Scholar2. Welch HG. The heterogeneity of cancer. Breast Cancer Res. Treat. 169(2), 207–208 (2018).Crossref, Medline, Google Scholar3. Treasure T, Leonard P, Milosevic M, Williams NR, Macbeth F, Farewell V. Pulmonary metastasectomy in colorectal cancer: the PulMiCC randomised controlled trial. Br. J. Surg. 107(11), e489–e490 (2020).Medline, Google Scholar4. Schweiger T, Lang G, Klepetko W, Hoetzenecker K. Prognostic factors in pulmonary metastasectomy: spotlight on molecular and radiological markers. Eur. J. Cardiothorac. Surg. 45(3), 408–416 (2014).Crossref, Medline, Google Scholar5. Lee JH, Gulec SA, Kyshtoobayeva A, Sim MS, Morton DL. Biological factors, tumor growth kinetics, and survival after metastasectomy for pulmonary melanoma. Ann. Surg. Oncol. 16(10), 2834–2839 (2009).Crossref, Medline, Google Scholar6. Handy JR, Bremner RM, Crocenzi TS et al. Expert consensus document on pulmonary metastasectomy. Ann. Thorac. Surg. 107(2), 631–649 (2019).Crossref, Medline, Google Scholar7. Escudier B, Porta C, Schmidinger M et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(5), 706–720 (2019).Crossref, Medline, CAS, Google Scholar8. Gronchi A, Miah AB, Dei Tos AP et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up(☆). Ann. Oncol. 32(11), 1348–1365 (2021).Crossref, Medline, CAS, Google Scholar9. Iida T, Nomori H, Shiba M et al. Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications: a retrospective analysis. Ann. Surg. 257(6), 1059–1064 (2013).Crossref, Medline, Google Scholar10. Milosevic M, Edwards J, Tsang D et al. Pulmonary metastasectomy in colorectal cancer: updated analysis of 93 randomized patients – control survival is much better than previously assumed. Colorectal. Dis. 22(10), 1314–1324 (2020).Crossref, Medline, CAS, Google Scholar11. Stein WD, Gulley JL, Schlom J et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy. Clin. Cancer Res. 17(4), 907–917 (2011).Crossref, Medline, CAS, Google Scholar12. Centers for Medicare and Medicaid Services. Medicare Coverage Database: Monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. www.cms.gov/medicare-coverage-database/view/ncacal-tracking-sheet.aspx?NCAId=305Google Scholar13. Ford I, Norrie J. Pragmatic trials. N. Engl. J. Med. 375(5), 454–463 (2016).Crossref, Medline, Google Scholar14. Horby P,Lim WS,Emberson JR et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 384(8), 693–704 (2020).Medline, Google Scholar15. Banerjee R, Prasad V. Pragmatic trials with prespecified subgroups: what oncologists can learn from COVID-19. Nat. Rev. Clin. Oncol. 18(1), 7–8 (2021).Crossref, Medline, Google Scholar16. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine – reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357(21), 2189–2194 (2007).Crossref, Medline, CAS, Google Scholar17. Stein WD, Figg WD, Dahut W et al. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: a novel strategy for evaluation of clinical trial data. Oncologist 13(10), 1046–1054 (2008).Crossref, Medline, Google Scholar18. James S, Rao SV, Granger CB. Registry-based randomized clinical trials–a new clinical trial paradigm. Nat. Rev. Cardiol. 12(5), 312–316 (2015).Crossref, Medline, Google Scholar19. Cook JA. The challenges faced in the design, conduct and analysis of surgical randomised controlled trials. Trials 10, 9 (2009).Crossref, Medline, Google Scholar20. Olivier T, Pop D, Chouiter Djebaili A et al. Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence? Crit. Rev. Oncol. Hematol. 95(1), 62–77 (2015).Crossref, Medline, Google Scholar21. Van Geel AN, Pastorino U, Jauch KW et al. Surgical treatment of lung metastases: the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group study of 255 patients. Cancer 77(4), 675–682 (1996).Crossref, Medline, CAS, Google Scholar22. Harris E, Barry M, Kell MR. Meta-analysis to determine if surgical resection of the primary tumour in the setting of stage IV breast cancer impacts on survival. Ann. Surg. Oncol. 20(9), 2828–2834 (2013).Crossref, Medline, Google Scholar23. Badwe R, Hawaldar R, Nair N et al. Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol. 16(13), 1380–1388 (2015).Crossref, Medline, Google ScholarFiguresReferencesRelatedDetails Vol. 18, No. 36 eToC Sign up Follow us on social media for the latest updates Metrics Downloaded 10 times History Received 22 August 2022 Accepted 2 November 2022 Published online 9 January 2023 Published in print November 2022 Information© 2023 Future Medicine LtdKeywordsbiomarkersclinical trialsmetastasismolecular oncologyoncogenessurgerySupplementary dataTo view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/fon-2022-0840Author contributionsV Prasad conceptualized the study design; K Powell and J Marquart reviewed literature; T Olivier performed statistical analysis; V Prasad, T Olivier and J Marquart reviewed and confirmed abstracted data; K Powell wrote the first draft of the manuscript; and all authors reviewed and revised subsequent and finalized drafts of the manuscript.Financial & competing interests disclosureV Prasad discloses research funding from Arnold Ventures; royalties from Johns Hopkins Press, Medscape and MedPage; consulting fees from UnitedHealthcare and OptumRx; and subscriber fees from Patreon, YouTube and Substack. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download